ArticlePloS one2026

Cancer risk associated with DPP4 inhibitors in type 2 diabetes: A pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS).

Wan Xiong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.